Abstract
The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu receptors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinsons disease has triggered an intense search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors.
Keywords: CPCCOEt, positive allosteric modulators, signal transduction, Fenobam, LY354740
Current Neuropharmacology
Title: Allosteric Modulators for mGlu Receptors
Volume: 5 Issue: 3
Author(s): F. Gasparini and W. Spooren
Affiliation:
Keywords: CPCCOEt, positive allosteric modulators, signal transduction, Fenobam, LY354740
Abstract: The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu receptors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinsons disease has triggered an intense search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors.
Export Options
About this article
Cite this article as:
Gasparini F. and Spooren W., Allosteric Modulators for mGlu Receptors, Current Neuropharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157015907781695900
DOI https://dx.doi.org/10.2174/157015907781695900 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In-Vitro and In-Vivo Pharmacological Activities with Phytochemical Evaluation of Methanolic Extract of Microcos paniculata Stem Barks
Current Drug Therapy Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design Cerebral Palsy: Classification, Etiology and Evolution of Spine Deformity in Children and Adolescents
Current Pediatric Reviews Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Innovative In Silico Approaches to Address Avian Flu Using Grid Technology
Infectious Disorders - Drug Targets The Cone Beam O-Arm Imaging System: Radiation Dose, Image Quality, and Clinical Applications
Recent Patents on Medical Imaging Male Contraception: An Overview of the Potential Target Events
Endocrine, Metabolic & Immune Disorders - Drug Targets Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Review of Patents on Microneedle Applicators
Recent Patents on Drug Delivery & Formulation On the Role of Endothelial TRPC3 Channels in Endothelial Dysfunction and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry AKT: A Potential Target for Thyroid Cancer Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Therapeutic Effects of Melatonin On Liver And Kidney Damages In Intensive Exercise Model of Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Disorders of Primary Metabolites in Response to Drought May Increase the Synthesis of Natural Products for Medicinal Purposes: South American Herbs - a Case Study
Recent Patents on Biotechnology Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Botulinum Toxin: A Successful Therapeutic Protein
Current Medicinal Chemistry Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine The Retinal Pigment Epithelium in Health and Disease
Current Molecular Medicine